Patients with acute myocarditis and advanced atrioventricular block (AVB) may be identified through elevated extracellular volume (ECV) in the basal superior ventricular septum, according to a retrospective study published in Clinical Radiology. Researchers found that this specific cardiac magnetic resonance (CMR) imaging marker correlates with adverse clinical outcomes, offering a potential tool for future risk stratification in cardiac care.
How CMR Imaging Identifies Risk in Myocarditis
Cardiac magnetic resonance imaging has become a standard for assessing inflammation in the heart muscle. In a study of 105 patients admitted with acute myocarditis between June 2018 and April 2024, researchers led by R. Liao evaluated how tissue parameters differ among patients with varying degrees of conduction block. The cohort included 53 patients without AVB, 34 with non-advanced AVB, and 18 with advanced AVB.
The study, titled Feasibility of cardiac magnetic resonance for assessing atrioventricular block in acute myocarditis, found that while most patients showed no active AVB during their CMR scan, those who had experienced advanced AVB displayed higher ECV values across multiple myocardial segments. Specifically, the basal superior ventricular septum served as the most reliable indicator, with a threshold of 36.95% helping distinguish between advanced and non-advanced cases.
Acute myocarditis is an inflammatory condition that can temporarily disrupt the heart’s electrical pathways. Because these conduction disturbances are often transient, finding a permanent imaging marker has historically been a significant clinical challenge for cardiologists.
Connecting Imaging Markers to Clinical Outcomes
The clinical significance of these findings lies in the link between elevated ECV and patient prognosis. According to the study data, adverse clinical outcomes—defined as death, heart failure requiring readmission, or the need for a cardiac device like an implantable cardioverter-defibrillator (ICD)—occurred exclusively in patients with both advanced AVB and elevated ECV in the basal superior ventricular septum.
This correlation reached statistical significance with a p-value of 0.016. While the sample size for these adverse events was small, the consistency of the findings suggests that CMR-derived ECV could eventually play a role in identifying which myocarditis patients require closer monitoring or more aggressive intervention.
Why Further Validation is Necessary
Despite these promising results, the researchers note that the study’s retrospective, single-centre design limits immediate clinical application. Before basal septal ECV can be adopted into routine risk assessment pathways, larger, multi-centre trials are required to validate the 36.95% threshold.
Comparing the tissue parameters, researchers observed that while ECV values varied significantly in the basal superior ventricular septum, other tissue parameters did not show the same level of differentiation between advanced and non-advanced AVB subgroups. This specificity highlights the potential for focused imaging protocols in future cardiac diagnostic workflows.
When reviewing CMR reports for myocarditis, focus on septal tissue characterization. As research evolves, localized ECV measurements may become a standard metric for predicting conduction stability.
Frequently Asked Questions
- What is the primary marker for advanced AVB in myocarditis?
According to the study, elevated extracellular volume (ECV) in the basal superior ventricular septum is a key imaging marker, with a threshold of 36.95% identified in the cohort. - Is AVB always permanent in myocarditis patients?
No. The study confirms that conduction disturbances in acute myocarditis are often transient, as most patients showed no evidence of ongoing AVB at the time of their CMR examination. - What are the risks associated with advanced AVB in this context?
Adverse outcomes include heart failure decompensation, the need for hospital readmission, or the requirement for a cardiac device such as an ICD or cardiac resynchronisation therapy.
Are you a medical professional interested in the latest cardiac imaging protocols? Subscribe to our clinical newsletter to receive updates on emerging research and diagnostic advancements.
